Show simple item record

dc.contributor.authorRA-MAP Consortium
dc.date.accessioned2020-04-27T09:22:26Z
dc.date.available2018-07-06
dc.date.available2020-04-27T09:22:26Z
dc.date.issued2018-10-25
dc.identifier.issn2056-5933
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/63758
dc.description.abstractObjectives: To identify predictors of remission and disease activity patterns in patients with rheumatoid arthritis (RA) using individual participant data (IPD) from clinical trials. Methods: Phase II and III clinical trials completed between 2002 and 2012 were identified by systematic literature review and contact with UK market authorisation holders. Anonymised baseline and follow-up IPD from non-biological arms were amalgamated. Multiple imputation was used to handle missing outcome and covariate information. Random effects logistic regression was used to identify predictors of remission, measured by the Disease Activity Score 28 (DAS28) at 6 months. Novel latent class mixed models characterised DAS28 over time. Results: IPD of 3290 participants from 18 trials were included. Of these participants, 92% received methotrexate (MTX). Remission rates were estimated at 8.4%(95%CI 7.4%to9.5%) overall, 17%(95%CI 14.8%to19.4%) for MTX-naïve patients with early RA and 3.2% (95% CI 2.4% to 4.3%) for those with prior MTX exposure at entry. In prior MTX-exposed patients, lower baseline DAS28 and MTX reinitiation were associated with remission. In MTX-naïve patients, being young, white, male, with better functional and mental health, lower baseline DAS28 and receiving concomitant glucocorticoids were associated with remission. Three DAS28 trajectory subpopulations were identified in MTX-naïve and MTX-exposed patients. A number of variables were associated with subpopulation membership and DAS28 levels within subpopulations. Conclusions : Predictors of remission differed between MTX-naïve and prior MTX-exposed patients at entry. Latent class mixed models supported differential non-biological therapy response, with three distinct trajectories observed in both MTX-naïve and MTX-exposed patients. Findings should be useful when designing future RA trials and interpreting results of biomarker studies.en_US
dc.format.extente000721
dc.languageeng
dc.publisherBMJen_US
dc.relation.ispartofRMD Open
dc.rightsThis is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0
dc.subjectDAS28 trajectoriesen_US
dc.subjectlatent class mixed modelsen_US
dc.subjectmethotrexateen_US
dc.subjectrandomised controlled trialen_US
dc.subjectremissionen_US
dc.subjectrheumatoid arthritisen_US
dc.titleNovel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data.en_US
dc.typeArticleen_US
dc.rights.holder© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ.
dc.identifier.doi10.1136/rmdopen-2018-000721
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30487994en_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume4en_US
dcterms.dateAccepted2018-07-06
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record